Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, R. Bahiri, Redouane Niamane et al.|Rheumatology International|2021Cited by 9
The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies.Meryem Eddaoudi, R. Bahiri, S. Rostom et al.|PubMed|2021Cited by 6
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR StudyLamia Oulkadi, R. Bahiri, S. Rostom et al.|Mediterranean Journal of Rheumatology|2022Cited by 5
The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal StudyS. Zemrani, R. Bahiri, Bouchra Amine et al.|Cureus|2024Cited by 2
The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapiesMeryem Eddaoudi, R. Bahiri, S. Rostom et al.|Research Square|2020Cited by 2